The GLP-1 Revolution
The development of GLP-1 receptor agonists represents one of the most significant advances in metabolic medicine. For the first time, we have medications that can produce 15-25% body weight loss — results that were previously only achievable through bariatric surgery. But these compounds do far more than just reduce weight.
How GLP-1 Agonists Work
GLP-1 (glucagon-like peptide-1) is an incretin hormone naturally released from the gut after eating. GLP-1 receptor agonists mimic and amplify this signal:
- Appetite Suppression: Activate GLP-1 receptors in the hypothalamus, reducing hunger and increasing satiety
- Slowed Gastric Emptying: Food stays in the stomach longer, prolonging fullness
- Improved Insulin Sensitivity: Enhance glucose-dependent insulin secretion
- Reduced Glucagon: Suppress inappropriate glucagon release
- Cardiovascular Benefits: Reduce inflammation, improve endothelial function
Semaglutide (Ozempic/Wegovy)
The first GLP-1 agonist to achieve mainstream recognition. Available as weekly injection (Ozempic for diabetes, Wegovy for weight management) and daily oral tablet (Rybelsus).
Key Trial Results (STEP Program):
- Average weight loss: 14.9-16.9% of body weight over 68 weeks
- Significant improvements in cardiovascular risk factors
- SELECT trial: 20% reduction in major adverse cardiovascular events
Dosing: Titrated up slowly over 16-20 weeks to minimize GI side effects. Target dose: 2.4 mg/week for weight management.
Tirzepatide (Mounjaro/Zepbound)
A dual GIP/GLP-1 receptor agonist that has shown even more impressive results than semaglutide.
Key Trial Results (SURMOUNT Program):
- Average weight loss: 20-26% of body weight at highest dose
- Up to 36% of participants lost >25% of body weight
- Superior to semaglutide in head-to-head trials
Dosing: Titrated from 2.5 mg to 5, 10, or 15 mg weekly.
Other Metabolic Compounds
AOD-9604
A modified fragment of growth hormone (amino acids 176-191) that retains fat-burning properties without the growth-promoting effects. Milder than GLP-1 agonists but with fewer side effects.
MOTS-c
A mitochondrial-derived peptide that acts as an exercise mimetic, improving metabolic homeostasis and insulin sensitivity through AMPK activation.
Managing Side Effects
The most common side effects of GLP-1 agonists are gastrointestinal:
- Nausea: Most common, usually improves over time. Slow titration helps.
- Constipation: Increase fiber and water intake
- Reduced appetite: This is the mechanism of action, but ensure adequate protein intake (minimum 1g/lb of lean body mass)
- Muscle loss: A real concern — resistance training and high protein intake are essential
Preserving Muscle Mass
One of the biggest concerns with rapid weight loss is muscle loss. Strategies to minimize this:
- High protein intake: 1-1.2g per pound of lean body mass
- Resistance training: 3-4 sessions per week
- Creatine supplementation: 5g daily
- Consider GH secretagogues: CJC-1295/Ipamorelin may help preserve lean mass
- Adequate sleep: 7-9 hours for optimal recovery and hormone production
The Weight Regain Problem
Studies show significant weight regain after discontinuing GLP-1 agonists — approximately 2/3 of lost weight is regained within a year. This suggests:
- These medications may need to be used long-term for sustained results
- Lifestyle modifications during treatment are crucial for maintaining results
- Dose reduction (rather than complete cessation) may be an option
- Building metabolically active tissue (muscle) during treatment helps
Who Should Consider GLP-1 Agonists?
These medications are most appropriate for individuals with:
- BMI ≥30 (or ≥27 with weight-related comorbidities)
- Failed attempts at lifestyle-based weight loss
- Metabolic syndrome or type 2 diabetes
- Cardiovascular risk factors
They are not appropriate as casual weight loss aids for individuals at healthy body weights.